After two U.S. acquisitions back in February, Quotient Clinical has been renamed as Quotient Sciences, and right after that, made another purchase.
U.K.-based CDMO Pharmaterials is now part of the rebranded Quotient Sciences. Quotient said in a release that the acquisition strengthens its formulation and manufacturing services footprint in its home country.
Services offered at Pharmaterials fall within Quotient’s existing portfolio, including characterization and optimization of small-molecule drug physical forms, the development of preclinical and clinical formulations, as well as contract manufacturing for clinical use and commercial supply.
Founded in 2000, Pharmaterials has established 13 GMP manufacturing suites in a 48,000-square-feet facility, which also has more space for future expansion.
Quotient entered the U.S. market through two closely announced acquisitions in February—clinical pharmacology expert Seaview and Charles River Laboratories’ CDMO unit QS Pharma.
“Quotient’s overall strategy behind the acquisitions over the last 12 months is to replicate our Translational Pharmaceutics platform in the USA,” Quotient spokesperson Robin Bodicoat told FierceCRO.
The platform works by combining services from traditional CDMOs with those from CROs, namely integrating formulation development and early-stage clinical research with GMP manufacturing. The company said the approach is proven to reduce drug development costs and shorten timelines.
After these acquisitions, Quotient now has 700 employees working at five sites in the U.S. and the U.K.
By Angus Liu
Source: Fierce Biotech
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.